AI Insights in Pharma with Protai - Life Sciences Today Podcast Episode 50

Why It Matters

ProtAI’s blend of AI and structural proteomics could slash drug‑development timelines, giving pharma companies faster access to high‑precision candidates and reshaping the economics of biotech innovation.

Key Takeaways

• ProtAI combines structural proteomics with AI for drug design.
• Their platform achieves sub‑angstrom protein models beyond AlphaFold averages.
• Lead candidate targets estrogen‑receptor positive breast cancer, entering trials soon.
• Business model mixes pharma collaborations and internal pipeline licensing.
• Proprietary in‑house data and chemical IP create a defensible moat.

Summary

In episode 50 of the Life Sciences Today podcast, host Danny Lieberman sits down with Carol Pesner, CTO and co‑founder of ProtAI, to discuss the company’s AI‑driven approach to drug discovery. ProtAI fuses structural proteomics with advanced artificial intelligence to generate sub‑atomic resolution models of target proteins, a capability they argue surpasses the average‑case performance of AlphaFold, the Nobel‑winning protein‑folding AI. The conversation highlights how this high‑resolution modeling enables rapid design of small‑molecule therapeutics, exemplified by their lead candidate for estrogen‑receptor positive breast cancer, which they expect to enter clinical trials within a year. By integrating proprietary proteomics data with AI, ProtAI claims to accelerate candidate selection from the industry‑standard three‑year timeline down to roughly twelve months, dramatically cutting cost and risk. Listeners hear concrete examples, such as the company’s internal pipeline progress and its collaborative licensing strategy with pharma and biotech partners. Pesner emphasizes that while AI informs decision‑making, experimental validation remains the ultimate proof, and the firm safeguards its advantage through unique in‑house datasets and chemical‑matter IP. The broader implication is a potential shift in the drug‑development ecosystem: technology firms that not only provide platforms but also bring drugs to market can capture greater value, challenge traditional R&D timelines, and offer pharma partners faster, more precise therapeutic candidates.

Original Description

We're excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Kiril Pevsner, Co-Founder and CTO at Protai. We kick this episode off by discussing how Pevsner creates and captures value with pharma. Then we talk about where AI meaningfully shapes decisions in the early discovery and preclinical work. Next, we take a look at where pharma teams hesitate to act on AI-driven insights, even when the science looks strong. We conclude this episode with Pevsner sharing where he doesn't think AI should be used in drug discovery or development, at least with today's tools and incentives.

For more great episodes of our Life Sciences Today Podcast, check out: https://www.healthcareittoday.com/category/life-sciences-today-podcasts/